Camallergy – short for Cambridge Allergy Ltd – is a biopharmaceutical company spun out from Cambridge University Hospitals that provides innovative treatments for the millions of people who live with food allergies. Camallergy’s lead product, CA002, is an oral immunotherapy for the treatment of peanut allergy that provides protection to patients within 14 weeks of therapy. It achieved best-in-class results in over 300 children treated in a phase 2 trial. The key to this success is a combination of the natural compound used in the treatment and Camallergy’s patented treatment regimen that creates a win/win/win scenario: it’s more effective, safer, and easy to take. Allergy physician key opinion leaders strongly prefer this medicine over the current

options. The company’s IND is accepted by the FDA for phase 3 trials initiating in Q1 2023


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.